AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05183997
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug will be add to prolong the effect of regional block
Trial: NCT05977699
Drug: salbutamol pressurized metered dose inhaler
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
Trial: NCT04748926
Drug: rilzabrutinib SAR444671
RxNorm normalized name: Rilzabrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: caplet Route of administration: oral
Trial: NCT00002131
Drug: Vesnarinone
RxNorm normalized name: VESNARINONE
DrugBank: Vesnarinone (DB12082)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04748926
Drug: rilzabrutinib SAR444671
RxNorm normalized name: Rilzabrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
Trial: NCT04748926
Drug: rilzabrutinib SAR444671
RxNorm normalized name: Rilzabrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
Trial: NCT05832489
Drug: Methylphenidate immediate release 25mg
RxNorm normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days.
Trial: NCT05602961
Drug: GLB-COV2-043
RxNorm normalized name: REGN-COV2
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine, administered as a booster
Trial: NCT06240403
Drug: Digoxin 0.125 MG
RxNorm normalized name: digoxin 0.125 MG
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule containing digoxin per day for three months
Trial: NCT06645522
Drug: Edaravone dexborneol
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
Trial: NCT06107205
Drug: Radicava
RxNorm normalized name: Radicava
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
Trial: NCT06107205
Drug: Radicava ORS
RxNorm normalized name: Radicava ORS
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
Trial: NCT05320198
Drug: DISC-0974
RxNorm normalized name: xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DISC-0974 is administered subcutaneously.
Trial: NCT04856631
Drug: Toripalimab Injection
RxNorm normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg once per 3 weeks
Trial: NCT04856631
Drug: Cetuximab Solution for infusion
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
Trial: NCT05665348
Drug: Ipilimumab Injection
RxNorm normalized name: ipilimumab Injection
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
Trial: NCT05258799
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
Trial: NCT05665348
Drug: Atezolizumab Injection
RxNorm normalized name: atezolizumab Injection
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One of the standard treatment's product for HCC management
Trial: NCT05665348
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One of the standard treatment's product for HCC management
Trial: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
RxNorm normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
Trial: NCT06025630
Drug: TUDCA
RxNorm normalized name: TUDCA
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
Trial: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
RxNorm normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
Trial: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
RxNorm normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56
Trial: NCT05289687
Drug: Daratumumab / Hyaluronidase Injection
RxNorm normalized name: daratumumab / hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
Trial: NCT05298176
Drug: Afatinib, Osimertinib, Carboplatin and Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
Trial: NCT00002030
Drug: Pentamidine isethionate
RxNorm normalized name: Pentamidine Isethionate
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06201000
Drug: SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of dapagliflozin or empagliflozin
Trial: NCT04764383
Drug: L-Histidine
RxNorm normalized name: L-histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg capsules taken by mouth (PO) twice daily (BID).
Trial: NCT04764383
Drug: Lodosyn
RxNorm normalized name: Lodosyn
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg capsules taken PO BID.
Trial: NCT06083844
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06083844
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05473468
Drug: Famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
Trial: NCT04856397
Drug: Intravitreal Implant in Applicator
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone intravitreal implant
Trial: NCT04856397
Drug: Eylea
RxNorm normalized name: Eylea
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-VEGF medication
Trial: NCT05167331
Drug: Nitrous Oxide inhalation
RxNorm normalized name: nitrous oxide Inhalant Product
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
Trial: NCT06270017
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rsponse evaluation in zebrafish embryo model
Trial: NCT05746676
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in treatment of periodontal defects
Trial: NCT05746676
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in treatment of periodontal defects
Trial: NCT05104424
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
Trial: NCT06448195
Drug: Polyethylene Glycol Somatropin (rDNA origin) Injection
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specification: 54IU/9.0mg/1.0ml/ bottle Dosage form: injection; Dose: 1mg/ week. Subcutaneous injection (upper arm, thigh or abdomen periumbilical) for a total course of 6 months, a total of 3 bottles per patient
Trial: NCT05127824
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
Trial: NCT06095492
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient will get Empagliflozin 25
Trial: NCT06095492
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin 5 mg once a day
Trial: NCT06701149
Drug: Rademikibart injection
RxNorm normalized name: Rademikibart
DrugBank: Rademikibart (DB18995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg administered subcutaneously on the first day
Trial: NCT06701149
Drug: CBP-201 injection
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg administered subcutaneously on the first day
Trial: NCT06634199
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
Trial: NCT06716970
Drug: Sacubitril/valsartan 200mg
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sacubitril/valsartan 200mg QD
Trial: NCT06716970
Drug: Sacubitril/valsartan 200mg placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Matching placebo of Sacubitril/valsartan 200mg QD
Trial: NCT05022628
Drug: Donafenib
RxNorm normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donafenib treatment regimen.~1. Donafenib started on the day of the first radiation treatment.~2. starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~3. Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~4. Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment.
Trial: NCT06721286
Drug: Teripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
Trial: NCT06721286
Drug: Gemcitabine + Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
Trial: NCT06719934
Drug: Dienogest 2 mg orally
RxNorm normalized name: dienogest 2 MG
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg Dienogest orally
Trial: NCT00055510
Drug: BO-653
RxNorm normalized name: BO-653
DrugBank: BO-653 (DB19216)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06719986
Drug: Nalmefene HCl injection
RxNorm normalized name: nalmefene Injection
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
Trial: NCT06719986
Drug: Naloxone HCl intranasal
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone 4 mg for intranasal (IN) administration
Trial: NCT06720220
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: procedural sedation by I.V. infusion of dexmedetomidine. It was prepared as 200 ug (2 ml) of dexmedetomidine added to 48 ml of 0.9% saline.~A loading dose of dexmedetomidine 0.5 to 1 ug/kg was given over 10- 20 minutes, followed by 0.2-0.7 ug/kg/hr as a continuous infusion by a syringe pump. During the dexmedetomidine infusion, a spontaneous respiratory pattern was maintained, and the level of sedation achieved to a point of semi-sleep but responds to commands (equivalent to Modified Ramsay Sedation Scale score of 3).
Trial: NCT06720025
Drug: SAL-0951 tablets
RxNorm normalized name: salicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Trial: NCT06720025
Drug: rHuEPO injection
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
Trial: NCT05266963
Drug: CREON
RxNorm normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will enroll 6-10 adult subjects with T1D who will receive both pancreatic enzyme replacement (CREON) or placebo each for 7 days in a random order. The effect of the intervention will be monitored by continuous glucose monitoring, diet recording, capsule counts, a mixed-meal tolerance test, and a survey to assess symptoms of PEI. This study design will allow for estimation of the effect of pancreatic enzyme replacement on the measured parameters.
Trial: NCT05567185
Drug: Erdafitinib Intravesical Delivery System
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erdafitinib intravesical delivery system will be administered.
Trial: NCT05954780
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
Trial: NCT04372108
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants who are new users of ustekunumab will be included in the cohort. No study treatment will be administered as a part of this study.
Trial: NCT06204120
Drug: morphine hydrochloride injection
RxNorm normalized name: morphine Injection
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCA administration
Trial: NCT04372108
Drug: Other Biologic Therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are new users of other biologic therapies (for examples for example, infliximab, adalimumab, or vedolizumab administered as per the prescription record) will be included in this cohort. No study treatment will be administered as a part of this study.
Trial: NCT04750655
Drug: Moxifloxacin (Topical)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
Trial: NCT05664711
Drug: Bupivacaine Injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug.
Trial: NCT06030258
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg D1, Q3W, intravenously
Trial: NCT06030258
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 mg/ml/min, D1, Q3W, intravenously
Trial: NCT06030258
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
Trial: NCT05157464
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
Trial: NCT05203822
Drug: Tepotinib (HydroChloride hydrate)
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
Trial: NCT05203822
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
Trial: NCT05510219
Drug: intravenous rapid infusion of obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
Trial: NCT06003881
Drug: Pozelimab
RxNorm normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration
Trial: NCT01170871
Drug: Ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01170871
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05273775
Drug: Midazolam Maleate Tablets
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam Maleate Tablets single dose
Trial: NCT05273775
Drug: Warfarin Sodium Tablets
RxNorm normalized name: Warfarin Sodium Tablets
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin Sodium Tablets single dose